{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T14:14:46Z","timestamp":1785766486037,"version":"3.56.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,12,26]],"date-time":"2019-12-26T00:00:00Z","timestamp":1577318400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,12,26]],"date-time":"2019-12-26T00:00:00Z","timestamp":1577318400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2020,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The influence of uric acid (UA) on renal function and the significance of UA-lowering therapy are unclear. The purpose of the sub-analysis of the Assessment of Clinical Usefulness in chronic kidney disease patients with Atorvastatin (ASUCA) trial was to evaluate the influence of serum UA levels on renal function in Japanese chronic kidney disease patients with hyperlipidemia.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Of 344 participants in the ASUCA trial, 279 participants whose UA levels at both baseline and 24\u00a0months were available were included. Based on UA level at baseline or mean UA level during the trial period, they were divided into four groups:\u2009&lt;\u20095.0, 5.0\u20136.0, 6.0\u20137.0, or\u2009\u2265\u20097.0\u00a0mg\/dL, irrespective of allocation. Changes in the estimated glomerular filtration rate (eGFR) after 24\u00a0months were compared among the groups in relation to baseline or mean UA levels.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>For baseline UA levels (&lt;\u20095.0, 5.0\u20136.0, 6.0\u20137.0, or\u2009\u2265\u20097.0\u00a0mg\/dL), the change in eGFR after 24\u00a0months was\u2009\u2212\u20091.32\u2009\u00b1\u200910.3,\u2009\u2212\u20091.74\u2009\u00b1\u20098.94,\u2009\u2212\u20092.53\u2009\u00b1\u20097.34, and\u2009\u2212\u20093.51\u2009\u00b1\u20099.10\u00a0mL\/min\/1.73\u00a0m<jats:sup>2<\/jats:sup>, respectively. A negative correlation between changes in eGFR after 24\u00a0months and baseline UA level was observed with adjustment for confounding factors. The relationship between changes in eGFR and mean UA levels during trial period showed a similar trend.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In CKD patients with dyslipidemia, hyperuricemia was an independent risk factor for CKD progression. An ongoing clinical trial (TARGET-UA, UMIN-ID 000,026,741) may reveal the significance of strict UA-lowering therapy in CKD patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10157-019-01840-4","type":"journal-article","created":{"date-parts":[[2019,12,26]],"date-time":"2019-12-26T06:18:31Z","timestamp":1577341111000},"page":"420-426","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The association between uric acid levels and renal function of CKD patients with hyperlipidemia: a sub-analysis of the ASUCA trial"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4161-2970","authenticated-orcid":false,"given":"Yoshihiro","family":"Kuwabara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Yasuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Kasahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Ueshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuwa","family":"Nakao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,26]]},"reference":[{"issue":"9","key":"1840_CR1","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1093\/ndt\/gft029","volume":"28","author":"RJ Johnson","year":"2013","unstructured":"Johnson RJ, Nakagawa T, Jalal D, S\u00e1nchez-Lozada LG, Kang DH, Ritz E. Uric acid and chronic kidney disease: which is chasing which? Nephrol Dial Transplant. 2013;28(9):2221\u20138.","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"1840_CR2","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/0002-9343(82)90593-9","volume":"72","author":"TF Y\u00fc","year":"1982","unstructured":"Y\u00fc TF, Berger L. Impaired renal function in gout. Its association with hypertensive vascular disease and intrinsic renal disease. Am J Med. 1982;72(1):95\u2013100.","journal-title":"Am J Med"},{"issue":"2","key":"1840_CR3","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/S0272-6386(99)70295-7","volume":"33","author":"RJ Johnson","year":"1999","unstructured":"Johnson RJ, Kivlighn SD, Kim YG, Suga S, Fogo AB. Reappraisal of the pathogenesis and consequences of hyperuricemia in hypertension, cardiovascular disease, and renal disease. Am J Kidney Dis. 1999;33(2):225\u201334.","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"1840_CR4","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1161\/hy1101.092839","volume":"38","author":"M Mazzali","year":"2001","unstructured":"Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension. 2001;38(5):1101\u20136.","journal-title":"Hypertension"},{"issue":"6","key":"1840_CR5","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1053\/j.ackd.2012.05.009","volume":"19","author":"DI Feig","year":"2012","unstructured":"Feig DI. Hyperuricemia and hypertension. Adv Chronic Kidney Dis. 2012;19(6):377\u201385.","journal-title":"Adv Chronic Kidney Dis"},{"issue":"1","key":"1840_CR6","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1159\/000066303","volume":"23","author":"T Nakagawa","year":"2003","unstructured":"Nakagawa T, Mazzali M, Kang DH, Kanellis J, Watanabe S, Sanchez-Lozada LG, et al. Hyperuricemia causes glomerular hypertrophy in the rat. Am J Nephrol. 2003;23(1):2\u20137.","journal-title":"Am J Nephrol"},{"issue":"5","key":"1840_CR7","doi-asserted-by":"publisher","first-page":"F471","DOI":"10.1152\/ajprenal.00560.2012","volume":"304","author":"E-S Ryu","year":"2013","unstructured":"Ryu E-S, Kim MJ, Shin H-S, Jang Y-H, Choi HS, Jo I, et al. Uric acid-induced phenotypic transition of renal tubular cells as a novel mechanism of chronic kidney disease. AJP Ren Physiol. 2013;304(5):F471\u2013F480480.","journal-title":"AJP Ren Physiol"},{"key":"1840_CR8","doi-asserted-by":"publisher","first-page":"F625","DOI":"10.1152\/ajprenal.00140.2005","volume":"290","author":"T Nakagawa","year":"2006","unstructured":"Nakagawa T, Hu H, Zharikov S, Tuttle KR, Short RA, Glushakova O, et al. A causal role for uric acid in fructose-induced metabolic syndrome. Am J Physiol Ren Physiol. 2006;290:F625\u2013F631631.","journal-title":"Am J Physiol Ren Physiol"},{"issue":"4","key":"1840_CR9","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/S0272-6386(04)00934-5","volume":"44","author":"K Iseki","year":"2004","unstructured":"Iseki K, Ikemiya Y, Inoue T, Iseki C, Kinjo K, Takishita S. Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis. 2004;44(4):642\u201350.","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"1840_CR10","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1053\/j.ajkd.2010.01.019","volume":"56","author":"G Bellomo","year":"2010","unstructured":"Bellomo G, Venanzi S, Verdura C, Saronio P, Esposito A, Timio M. Association of uric acid with change in kidney function in healthy normotensive individuals. Am J Kidney Dis. 2010;56(2):264\u201372.","journal-title":"Am J Kidney Dis"},{"issue":"11","key":"1840_CR11","first-page":"1","volume":"6","author":"H Ito","year":"2011","unstructured":"Ito H, Abe M, Mifune M, Oshikiri K, Antoku S, Takeuchi Y, et al. Hyperuricemia is independently associated with coronary heart disease and renal dysfunction in patients with type 2 diabetes mellitus. PLoS ONE. 2011;6(11):1\u20137.","journal-title":"PLoS ONE"},{"issue":"7","key":"1840_CR12","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.2337\/db09-0014","volume":"58","author":"P Hovind","year":"2009","unstructured":"Hovind P, Rossing P, Tarnow L, Johnson RJ, Parving HH. Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes: an inception cohort study. Diabetes. 2009;58(7):1668\u2013711.","journal-title":"Diabetes"},{"issue":"1","key":"1840_CR13","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1053\/j.ajkd.2005.10.006","volume":"47","author":"YP Siu","year":"2006","unstructured":"Siu YP, Leung KT, Tong MKH, Kwan TH. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis. 2006;47(1):51\u20139.","journal-title":"Am J Kidney Dis"},{"issue":"8","key":"1840_CR14","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.2215\/CJN.01580210","volume":"5","author":"M Goicoechea","year":"2010","unstructured":"Goicoechea M, De Vinuesa SG, Verdalles U, Ruiz-Caro C, Ampuero J, Rinc\u00f3n A, et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol. 2010;5(8):1388\u201393.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"1840_CR15","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1159\/000105142","volume":"27","author":"KM Talaat","year":"2007","unstructured":"Talaat KM, El-Sheikh AR. The effect of mild hyperuricemia on urinary transforming growth factor beta and the progression of chronic kidney disease. Am J Nephrol. 2007;27(5):435\u201340.","journal-title":"Am J Nephrol"},{"issue":"5","key":"1840_CR16","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1053\/j.ajkd.2008.12.021","volume":"53","author":"M Madero","year":"2009","unstructured":"Madero M, Sarnak MJ, Wang X, Greene T, Beck GJ, Kusek JW, et al. Uric acid and long-term outcomes in CKD. Am J Kidney Dis. 2009;53(5):796\u2013803.","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"1840_CR17","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.exger.2008.01.006","volume":"43","author":"G Sturm","year":"2008","unstructured":"Sturm G, Kollerits B, Neyer U, Ritz E, Kronenberg F. Uric acid as a risk factor for progression of non-diabetic chronic kidney disease? The mild to moderate kidney disease (MMKD) study. Exp Gerontol. 2008;43(4):347\u201352.","journal-title":"Exp Gerontol"},{"issue":"2","key":"1840_CR18","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s10157-012-0676-5","volume":"17","author":"K Ueshima","year":"2013","unstructured":"Ueshima K, Kasahara M, Koya D, Babazono T, Sato T, Imamoto M, et al. Effects of atorvastatin on renal function in patients with dyslipidemia and chronic kidney disease: Rationale and design of the ASsessment of clinical Usefulness in CKD patients with Atorvastatin (ASUCA) trial. Clin Exp Nephrol. 2013;17(2):211\u20137.","journal-title":"Clin Exp Nephrol"},{"issue":"3","key":"1840_CR19","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s10157-016-1304-6","volume":"21","author":"G Kimura","year":"2017","unstructured":"Kimura G, Kasahara M, Ueshima K, Tanaka S, Yasuno S, Fujimoto A, et al. Effects of atorvastatin on renal function in patients with dyslipidemia and chronic kidney disease: assessment of clinical usefulness in CKD patients with atorvastatin (ASUCA) trial. Clin Exp Nephrol. 2017;21(3):417\u201324.","journal-title":"Clin Exp Nephrol"},{"key":"1840_CR20","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant. 2013;48:452\u20138.","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"1840_CR21","first-page":"F1134","volume":"295","author":"LG S\u00e1nchez-Lozada","year":"2008","unstructured":"S\u00e1nchez-Lozada LG, Soto V, Tapia E, Avila-Casado C, Sautin YY, Nakagawa T, et al. Role of oxidative stress in the renal abnormalities induced by experimental hyperuricemia. Am J Physiol. 2008;295(4):F1134\u20131141.","journal-title":"Am J Physiol"},{"issue":"4","key":"1840_CR22","doi-asserted-by":"publisher","first-page":"F1238","DOI":"10.1152\/ajprenal.00164.2006","volume":"292","author":"LG Sanchez-Lozada","year":"2007","unstructured":"Sanchez-Lozada LG, Tapia E, Lopez-Molina R, Nepomuceno T, Soto V, Avila-Casado C, et al. Effects of acute and chronic L-arginine treatment in experimental hyperuricemia. Am J Physiol Ren Physiol. 2007;292(4):F1238\u2013F12441244.","journal-title":"Am J Physiol Ren Physiol."},{"issue":"1","key":"1840_CR23","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/j.1523-1755.2005.00074.x","volume":"67","author":"LG S\u00e1nchez-Lozada","year":"2005","unstructured":"S\u00e1nchez-Lozada LG, Tapia E, Santamar\u00eda J, Avila-Casado C, Soto V, Nepomuceno T, et al. Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney Int. 2005;67(1):237\u201347.","journal-title":"Kidney Int"},{"issue":"12","key":"1840_CR24","doi-asserted-by":"publisher","first-page":"2888","DOI":"10.1097\/01.ASN.0000034910.58454.FD","volume":"13","author":"DH Kang","year":"2002","unstructured":"Kang DH, Nakagawa T, Feng L, Watanabe S, Han L, Mazzali M, et al. A role for uric acid in the progression of renal disease. J Am Soc Nephrol. 2002;13(12):2888\u2013977.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"1840_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12883-015-0273-9","volume":"15","author":"J Pakpoor","year":"2015","unstructured":"Pakpoor J, Seminog OO, Ramagopalan SV, Goldacre MJ. Clinical associations between gout and multiple sclerosis, Parkinson\u2019s disease and motor neuron disease: record-linkage studies. BMC Neurol. 2015;15(1):1\u20136.","journal-title":"BMC Neurol"},{"issue":"3","key":"1840_CR26","doi-asserted-by":"publisher","first-page":"278","DOI":"10.4103\/0019-5154.82480","volume":"56","author":"M Yousefi","year":"2011","unstructured":"Yousefi M, Rahimi H, Barikbin B, Toossi P, Lotfi S, Hedayati M, et al. Uric acid: a new antioxidant in patients with pemphigus vulgaris. Indian J Dermatol. 2011;56(3):278\u201381.","journal-title":"Indian J Dermatol"},{"issue":"4","key":"1840_CR27","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s00592-015-0825-x","volume":"53","author":"Y Hayashino","year":"2016","unstructured":"Hayashino Y, Okamura S, Tsujii S, Ishii H. Association of serum uric acid levels with the risk of development or progression of albuminuria among Japanese patients with type 2 diabetes: a prospective cohort study [Diabetes Distress and Care Registry at Tenri (DDCRT 10)]. Acta Diabetol. 2016;53(4):599\u2013607.","journal-title":"Acta Diabetol"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-019-01840-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10157-019-01840-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-019-01840-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,25]],"date-time":"2020-12-25T00:09:47Z","timestamp":1608854987000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10157-019-01840-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,26]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["1840"],"URL":"https:\/\/doi.org\/10.1007\/s10157-019-01840-4","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,26]]},"assertion":[{"value":"4 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"M. Kasahara report has received research funding and Honoraria from Daiichi-Sankyo Pharmaceuticals and Fuji-Yakuhin Pharmaceuticals. None of the other authors have any conflicts of interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The ASUCA trial was approved by the Ethics Committee at the Kyoto University Graduate School of Medicine (C-271) and conducted in accordance with the Declaration of Helsinki Principles and related ethical guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights (with IRB approval Number)"}},{"value":"Written informed consent was obtained from each subject enrolled in ASUCA trial.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}